Cellectis S.A. (NASDAQ:CLLS) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Cellectis S.A. (NASDAQ:CLLS) have received a consensus rating of “Moderate Buy” from the five brokerages that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $6.3333.

A number of analysts have recently issued reports on CLLS shares. Weiss Ratings restated a “sell (d-)” rating on shares of Cellectis in a report on Wednesday, January 21st. Clear Str raised Cellectis to a “strong-buy” rating in a research report on Tuesday, December 23rd. Jefferies Financial Group began coverage on shares of Cellectis in a report on Tuesday. They issued a “buy” rating and a $7.00 price objective on the stock. Finally, Wells Fargo & Company reaffirmed a “positive” rating and set a $4.00 target price on shares of Cellectis in a research note on Monday, October 20th.

Institutional Trading of Cellectis

A number of large investors have recently made changes to their positions in CLLS. Global Retirement Partners LLC acquired a new position in Cellectis during the fourth quarter worth approximately $34,000. Millennium Management LLC raised its position in Cellectis by 61.9% in the 3rd quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock valued at $165,000 after purchasing an additional 22,080 shares during the last quarter. Delaney Dennis R acquired a new stake in Cellectis during the 3rd quarter worth $68,000. B Group Inc. boosted its stake in Cellectis by 0.8% during the 3rd quarter. B Group Inc. now owns 3,281,501 shares of the biotechnology company’s stock worth $9,352,000 after purchasing an additional 25,000 shares during the period. Finally, Virtu Financial LLC purchased a new position in Cellectis during the 3rd quarter worth $72,000. 63.90% of the stock is currently owned by hedge funds and other institutional investors.

Cellectis Stock Performance

Shares of Cellectis stock opened at $3.73 on Tuesday. The firm has a fifty day moving average price of $4.28 and a 200 day moving average price of $3.77. Cellectis has a 1 year low of $1.10 and a 1 year high of $5.48. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.49 and a quick ratio of 1.49.

About Cellectis

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.